# CAMPERR (Adela methylome test for early detection and residual disease)

Source: https://onco.cc/trials/camperr/  
OnCo record `camperr` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Adela's study of about 7,000 people building a blood test that reads DNA methylation to find many cancers early and to track cancer after treatment.

## Summary

CAMPERR (NCT05366881) is an observational study sponsored by Adela, Inc. It trains and validates a genome-wide methylome enrichment platform to detect multiple cancer types and tell them apart, and to detect residual disease after treatment.

The registry record, read on 29 October 2026, gives its status as recruiting, with an estimated 7,000 participants, a start on 3 May 2022 and primary completion expected in March 2026.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-29
- Also known as: CAMPERR
- Registry id: NCT05366881
- Phase: observational
- Setting: People with any of 20 cancer types and people without cancer at US sites, in a case-control study of a genome-wide methylome enrichment platform
- Sponsor: Adela, Inc
- Enrolled: 7000

## Sources

- ClinicalTrials.gov NCT05366881: https://clinicaltrials.gov/study/NCT05366881

## Connected records

- fronts: [Early Detection & Screening](https://onco.cc/fronts/early-detection/)
- technologies: [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/), [Multi-cancer early detection (MCED)](https://onco.cc/technologies/mced/)
- drugs: [Adela multi-cancer methylome test](https://onco.cc/drugs/adela-mced/)
- companies: [Adela](https://onco.cc/companies/adela/)

---
JSON: https://onco.cc/api/v1/entities/camperr.json